Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349871 | 0.88 | HCAR2 (0.71) | HCAR2CYP2C9CYP2C8 | |
| SCHEMBL14349859 | 0.83 | HCAR2 (0.79) | HCAR2CYP2C9CYP2C8KDM4EHSD17B10 | |
| SCHEMBL14349875 | 0.83 | HCAR2 (0.81) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL14349870 | 0.80 | HCAR2 (0.63) | HCAR2CYP2C9CYP2C8KMT2AKDM4E | |
| SCHEMBL14349860 | 0.80 | HCAR2 (0.57) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL14349876 | 0.79 | HCAR2 (0.81) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL14349877 | 0.76 | HCAR2 (0.70) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL11717263 | 0.75 | MEN1 (0.67) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL14349872 | 0.74 | HCAR2 (0.56) | HCAR2CYP2C9CYP2C8MEN1KMT2A | |
| SCHEMBL14349790 | 0.72 | HCAR2 (1.00) | HCAR2CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | HCAR2 20/4885CYP2C9 973/4885CYP2C8 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.